evipedia.ai
← Back

Maca for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: Lepidium meyenii, Lepidium peruvianum, Maca Root, Peruvian Ginseng, Ayak Chichira, Maka

Motivation

Maca (Lepidium meyenii) is a root vegetable in the mustard family, grown above 4,000 metres in the Peruvian Andes and eaten there as a staple food for centuries. Dried and powdered, it is now sold worldwide as a supplement, mostly on claims about sexual desire, energy and the symptoms of menopause. What makes it unusual among such products is that it appears to work, when it works at all, without changing sex-hormone levels — an observation that has shaped how researchers look at it.

Andean growers have long fed maca to people and livestock to improve fertility and stamina at altitude. Interest outside Peru grew sharply from the late 1990s, and demand rose fast enough to move cultivation abroad and reshape the local trade. Controlled trials followed the commercial wave rather than preceding it, and most have been small.

This review examines what those trials and the reviews built on them establish about maca: which effects are supported, how large they are, where the evidence conflicts, what harms have been documented, and how the compound is used in practice.

Benefits - Risks - Protocol - Conclusion

A short list of high-level, non-systematic sources that give useful overviews of maca from clinical, expert and commentary perspectives.

Content from Rhonda Patrick, Peter Attia and Lifespan.io is absent from this list because peterattiamd.com and lifespan.io returned nothing on maca, and foundmyfitness.com carries only a single-clause mention inside a study summary on testosterone-regulating foods, too slight to qualify; the five items above are the qualifying sources found.

Grokipedia

  • Maca

    A long-form encyclopedia entry covering botany, phytochemistry, traditional Andean use, the clinical trial record and the modern commodity trade, with a denser treatment of cultivation and trade history than clinical sources give.

Examine

  • Maca

    Grades each maca outcome separately against the trial record, and its safety section is unusually concrete on product quality, documented adulteration and the testosterone-assay problem.

ConsumerLab

  • Maca Supplements Review & Top Picks

    The only independent laboratory testing of retail maca: identity confirmation by deoxyribonucleic acid and microscopy across eleven products, with one failed for lead and one suspected of rice filler.

Systematic Reviews

The pooled evidence on maca, drawn from systematic reviews and meta-analyses of randomized controlled trials (RCTs — trials that assign participants to treatment or placebo by chance).

Maca’s principal documented harms are contamination and product adulteration, and no systematic review or meta-analysis covers either; that side of the trade-off is unrepresented above, and the Borrelli review’s adverse-event tally is the closest pooled safety evidence available.

Mechanism of Action

Maca is a food, not a single molecule, and three compound classes carry its activity. Macamides — fatty acid amides unique to this plant — inhibit fatty acid amide hydrolase (FAAH, the enzyme that destroys the body’s own cannabis-like messengers), raising endocannabinoid tone; this is the leading explanation for the central effects on mood and desire. Glucosinolates, chiefly glucotropaeolin, are cleaved to benzyl isothiocyanate, the reactive species behind maca’s antioxidant and cell-protective signals in laboratory work. The root also supplies gamma-aminobutyric acid (GABA, the brain’s main calming signal), polysaccharides, zinc and iron.

What maca does not do is act as a hormone. Controlled dosing for twelve weeks left testosterone, estradiol, luteinizing hormone (LH, the pituitary signal that tells the gonads to make sex hormones), follicle-stimulating hormone and prolactin unchanged, and yeast reporter assays detected no estrogenic or androgenic activity in maca extracts.

Two mechanistic readings therefore compete. One holds that maca acts centrally and non-hormonally, through endocannabinoid and dopamine signalling. The other holds that responses reflect nutrient repletion plus the large placebo effect typical of self-rated desire endpoints. Human pharmacokinetic data are thin: macamides are fat-soluble with short half-lives in animals, and maca has not shown meaningful inhibition of cytochrome P450 enzymes (CYP, the liver’s main drug-processing family).

Historical Context & Evolution

Maca was domesticated on the Junín plateau of central Peru and has been cultivated between roughly 4,000 and 4,500 metres for 1,300 to 2,000 years. Its original use was as food — the hypocotyl (the swollen underground stem that is the edible part) was boiled, baked, fermented into a drink or cooked as porridge — and as a traditional remedy for anemia, low fertility and respiratory complaints, given to livestock as well as people. Colonial-era records show it taken as tribute, the earliest documentary trace of its perceived value.

Serious pharmacological interest began in the 1990s, when groups at Universidad Peruana Cayetano Heredia in Lima ran the first controlled human studies. Their central finding — that maca raised self-rated sexual desire while leaving serum testosterone and estradiol untouched — is what moved the plant from ethnobotany into trial literature, and it has held up in later work.

From there the story is commercial as much as scientific. Marketed internationally as “Peruvian ginseng”, maca saw export demand rise steeply, cultivation spread to Yunnan in China, and prices spike then collapse. Beharry and Heinrich argued in 2018 that the health claims had outrun the data and that indigenous knowledge had been recast to fit a market. Their critique reads the evidence base as a whole; it does not refute individual trials, several of which remain positive and unretracted. Larger studies since, on altitude quality of life and aging-male symptoms, have not settled the question either way.

Expected Benefits

High 🟩 🟩 🟩

Increased Sexual Desire ⚠️ Conflicted

Maca raises self-rated sexual desire without moving hormones. A 12-week trial in healthy men found desire rising from week 8 at 1,500 and 3,000 mg daily, independent of mood and testosterone. Trained cyclists showed the same against placebo after 14 days, and adults whose libido was flattened by serotonin-raising antidepressants (drugs such as fluoxetine) improved on 3 g but not 1.5 g. But the largest trial, using spray-dried extract, beat placebo only at altitude. Net reading: the effect replicates on root powder and is inconsistent on extract.

Magnitude: In antidepressant-treated adults, the Arizona Sexual Experience Scale (a validated five-item questionnaire) fell from 22.8 to 16.9 on 3 g daily, roughly a six-point improvement, while 1.5 g daily produced no significant change.

Reduced Menopausal Symptom Burden

Women near and past menopause report milder symptoms on maca, again without hormonal change. A systematic review of four randomized trials found every one favouring maca on the Kupperman Menopausal Index or the Greene Climacteric Scale, both validated symptom inventories. A crossover trial at 3.5 g daily cut the psychological subscales against baseline and placebo, and a second crossover trial at 3.3 g daily reproduced the depression finding with no shift in estradiol or thyroid-stimulating hormone.

Magnitude: The direction is consistent — menopausal symptom scores fall relative to placebo at 3.3–3.5 g daily over six to twelve weeks — but the trials and the systematic review pooling them report no summary effect size for this outcome.

Improved Erectile Function and Aging-Male Symptoms

In men with mild erectile difficulty, or with the fatigue, low mood and sexual complaints of later life despite normal testosterone, maca improves validated function scores while leaving testosterone alone. Fifty men taking 2,400 mg of dry extract for 12 weeks gained more on the International Index of Erectile Function than placebo. Eighty men with normal testosterone on 5 g daily improved on the Aging Males’ Symptoms scale and the erectile index; that trial was co-authored by employees of two supplement companies standing to benefit from a positive result.

Magnitude: The erectile-function index rose 1.6 ± 1.1 points on maca versus 0.5 ± 0.6 on placebo over 12 weeks in mild erectile dysfunction — a real but small difference on a scale where 5 points is the usual threshold for a clinically obvious change.

Medium 🟩 🟩

The largest maca trial gave 3 g daily of spray-dried black or red extract to 175 adults for 12 weeks, at sea level and at altitude, and found mood, energy and self-rated health status improved over placebo, chronic mountain sickness scores falling, with red maca outperforming black. This is one trial with self-reported endpoints from a group that has published on maca for three decades. It is nonetheless well powered for this field, and its two active arms diverged, which placebo response alone does not explain.

Magnitude: On mood at low altitude, red maca separated from placebo with a standardized effect size (Cohen’s d) of 1.14 and black maca 0.43 at 3 g daily over 12 weeks. Effects were smaller at high altitude, where mood reached 0.68 for red maca and the energy scale showed only a placebo response.

Lower Diastolic Blood Pressure ⚠️ Conflicted

Twenty-nine postmenopausal Chinese women taking 3.3 g of maca daily for six weeks in a crossover design showed a significant fall in diastolic blood pressure. Blood pressure is a surrogate validated against hard cardiovascular outcomes, which is why a modest shift matters more than its size suggests. But the larger extract trial in 175 adults measured blood pressure as a primary outcome and found no change against placebo. Net reading: the fall rests on one small trial of root powder and does not carry to extract.

Magnitude: The direction is a fall in diastolic pressure at 3.3 g daily over six weeks in postmenopausal women, with systolic pressure unchanged; that trial reports the change as statistically significant without a millimetre-of-mercury figure, while the larger extract trial reports no blood-pressure change at all.

Reduced Lower Urinary Tract Symptoms

Maca improved urinary symptoms in aging men — an outcome almost unexamined elsewhere in this literature. In the 12-week trial of 80 men with aging-male symptoms and normal testosterone, the International Prostate Symptom Score (a validated questionnaire covering urinary flow, urgency and night-time voiding) improved significantly against placebo, with prostate-specific antigen levels unchanged. The mechanism is unresolved; rodent work with red maca points to anti-inflammatory and androgen-receptor effects on prostate tissue. The trial’s supplement-company authorship, noted above, applies to this outcome too.

Magnitude: The urinary symptom score fell 2.3 points on 5 g daily over 12 weeks, from 13.9 to 11.6, while the placebo arm rose 1.4 points, from 13.2 to 14.6, a between-group difference at p = 0.0001 (p, the probability a difference this large would appear by chance alone; the smaller it is, the less likely that is); no second trial has measured this outcome.

Low 🟩

Endurance and Exercise Performance ⚠️ Conflicted

Eight cyclists improved 40 km time-trial performance against baseline but not placebo. A pooled analysis reported large effects, mostly from rodent tests, while 2,000 mg daily gave basketball players no gain in jump, sprint or lactate clearance. Net reading: the human signal disappears once placebo is controlled.

Magnitude: Direction in humans is null against placebo — no significant difference in countermovement jump (p = 0.352), fatigue index (p = 0.266) or lactate clearance (p = 0.258) — and no controlled human trial reports a positive effect size.

Semen Quality ⚠️ Conflicted

Pooling five randomized trials found no gain in sperm concentration, and 50 men with fertility problems saw concentration rise 40% on maca against 76% on placebo. Earlier uncontrolled work was positive. Net reading: controlled evidence does not support a fertility effect.

Magnitude: Sperm concentration differed from placebo by a weighted mean difference of 2.22 million/mL (the average gap across the pooled trials, with larger trials counting for more), and the 95% confidence interval (the range the true value most plausibly sits in) ran from −2.94 to 7.37, an interval that straddles zero.

Speculative 🟨

Antioxidant Defence

Pooled data show maca raising glutathione peroxidase and superoxide dismutase (antioxidant enzymes) and lowering malondialdehyde, a marker of oxidative fat damage. The basis is overwhelmingly cell-culture and rodent work; these are unvalidated biomarkers, not outcomes.

Cognitive and Neuroprotective Effects

Black maca reversed chemically induced memory loss in mice and preserved mitochondrial function in middle-aged mouse cortex. No controlled human trial has measured cognition, so the basis is animal and mechanistic only.

Benefit-Modifying Factors

  • Baseline symptom burden: Effects concentrate in people who start symptomatic. Desire gains appear in men with flattened libido and in menopausal women; trained cyclists with normal function showed nothing beyond placebo.

  • Sex and hormonal stage: Women’s benefit clusters around the menopausal transition, where symptom scales are the measured endpoint. Men’s clusters in the fifth decade and beyond, where aging-male and erectile indices are used.

  • Maca phenotype: Colour is not cosmetic. Black maca carries more macamides and fatty acids; red maca carries more gamma-aminobutyric acid and outperformed black on mood and energy, a split Minich et al. argue runs through the whole literature.

  • Altitude and high haemoglobin: Chronic mountain sickness scores fell in highlanders, where maca also lowered haemoglobin in those whose levels were abnormally high — an effect absent in lowlanders. Mood and energy gains were larger at low altitude.

  • Age: The age range studied runs from 21 to the mid-sixties. At the older end, benefit on urinary and aging-male symptom scores is the best-documented outcome; no trial has enrolled people over 70, so effects there are unmeasured.

  • Genetic variation in fatty acid amide hydrolase: The FAAH C385A variant slows breakdown of the body’s cannabis-like messengers and already raises baseline endocannabinoid tone; carriers may respond differently to a FAAH-inhibiting macamide load, though no maca trial has genotyped participants.

  • Pre-existing conditions: Depression and antidepressant-induced sexual dysfunction are the conditions where maca has been tested and shown benefit. Diabetes is untested, though black maca lowered blood glucose in healthy adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No maca risk reaches this level: no adverse outcome has been documented in more than one controlled trial, because the safety record consists of single-trial side-effect logs, isolated case reports and laboratory work rather than replicated clinical-event data.

Medium 🟥 🟥

Mild Gastrointestinal Upset

The most common complaint on maca is abdominal discomfort, nausea or loose stools, plausibly from the fermentable starch and glucosinolate content of a cruciferous root taken in gram quantities. In the 12-week randomized trial of 80 men, two participants in the maca arm reported gastrointestinal disorders; both were mild, neither withdrew, and no other treatment-related adverse effect was recorded. The largest maca trial similarly recorded good acceptability and no serious adverse effects across 175 adults on 3 g daily. Symptoms are reversible on stopping and usually on reducing the dose.

Magnitude: Two of 41 men on maca (roughly 5%) reported mild gastrointestinal symptoms over 12 weeks, none severe enough to stop treatment, against no excess of adverse events over placebo in pooled herbal-supplement trials.

Low 🟥

Lead Contamination and Product Adulteration

Maca concentrates soil minerals; retail powder has carried lead. One case traced a woman’s rising blood lead to daily maca powder; levels fell when she stopped. Independent testing failed one of eleven products for lead, and an analysis on Examine found one spiked with thiosildenafil, an unlicensed sildenafil analogue.

Magnitude: One case reached a whole-blood lead of 44 µg/dL from combined sources, with the maca-attributable rise and fall documented separately; one of eleven retail products failed independent lead testing, and one of 14 in another analysis was drug-adulterated.

Falsely Elevated Testosterone Readings

Maca interferes with some testosterone immunoassays, inviting unnecessary investigation. A woman on maca read 25.8 nmol/L against a reference limit below 2.9, with no physical signs of excess male hormone; a higher-affinity assay read the same sample at 2.9. The risk is diagnostic, not physiological, and underlies maca’s anti-doping caution.

Magnitude: A single documented case overstated total testosterone roughly ninefold, 25.8 nmol/L against a corrected 2.9 nmol/L, on one widely used immunoassay platform.

Adverse Events Alongside Antidepressants

A review of 1,816 adverse-event reports implicated adaptogenic herbs (plants marketed as stress-resistance aids) in 9% of events from combined antidepressant use; maca appeared once, with mianserin, producing restless legs syndrome. The proposed mechanism is side-effect aggregation plus interference with drug-metabolizing enzymes and transporters. The data are uncontrolled chart review.

Magnitude: One maca-attributable event in a 1,816-report series — restless legs syndrome on mianserin — within a class signal where adaptogens accounted for 9% of interaction-related adverse events.

Acute Liver Injury

A case report describes liver injury after one dose of maca medicinal liquor, with the liver enzyme alanine aminotransferase at 1,886 U/L and causality rated highly probable. The liquor was 50% alcohol; the mechanism is unknown. Bilirubin normalised over three months, enzymes only partly; no trial recorded injury on powder.

Magnitude: One published case, with alanine aminotransferase 1,886 U/L and total bilirubin 83.7 µmol/L, the bilirubin resolving over three months; no second case and no trial event, so no rate attaches to maca exposure.

Speculative 🟨

Sleep Disruption and Overstimulation

Reported side effects catalogued by independent testers include disturbed sleep, headache and increased sweating. No controlled trial has measured sleep on maca, so the basis is consumer reporting and isolated reports only.

Thyroid Suppression from Glucosinolates

Maca is a Brassicaceae root carrying glucosinolates, which in other cruciferous plants can impede iodine uptake. No human trial has shown thyroid change on maca; the concern is mechanistic extrapolation only.

Androgen Receptor and Prostate-Specific Antigen Upregulation

Red maca increased androgen receptor and prostate-specific antigen gene expression in a human prostate cancer cell line, without affecting cell viability. In-vitro gene expression only, with no human counterpart.

Alkaloid Burden

Regulators in Belgium, Germany and the United States have flagged maca’s imidazole, beta-carboline and pyrrole alkaloids, which vary widely across finished products. No human harm has been attributed to them.

Risk-Modifying Factors

  • Genetic variation: No polymorphism has been linked to maca’s side effects. The FAAH C385A variant alters endocannabinoid breakdown and is the mechanistic candidate, but no safety analysis has genotyped anyone exposed.

  • Source and lot: Contamination risk is a property of the batch, not the plant. Powder from unspecified origin, and Andean soils naturally rich in heavy metals, carry the lead exposure; certified low-metal lots essentially remove it.

  • Iodine status: The theoretical goitrogen concern from glucosinolates matters only where dietary iodine is already marginal. Adequate iodine intake neutralises it; no thyroid change was seen in trials.

  • Antidepressant use: People on serotonin-raising antidepressants, or on the older tetracyclic class (drugs such as mianserin and mirtazapine), carry the only documented drug-interaction signal, through overlapping side effects and shared metabolizing enzymes and transporters.

  • Pregnancy and lactation: Safety data are absent rather than reassuring in these states, and lead exposure matters far more to a developing fetus than to an adult.

  • Hormone-sensitive prostate disease: The androgen receptor and prostate-specific antigen signal is confined to cell culture, but men with prostate cancer or rising antigen levels carry the theoretical exposure others do not.

  • Liver impairment: A single case of acute liver injury after maca ingestion appears in safety databases, unreplicated in any trial; existing liver disease narrows the margin if that signal is real.

  • Age and baseline haemoglobin: Older adults and highlanders with abnormally high haemoglobin saw levels fall on maca — helpful where red-cell mass is already too high, unwanted in anyone already anaemic.

  • Competitive athletes: Maca is not on the prohibited list, but its testosterone-assay interference can generate a falsely elevated reading, which is a sanction risk rather than a health one.

Key Interactions & Contraindications

  • Antidepressants — tetracyclic and serotonin-raising (mianserin, mirtazapine, sertraline, escitalopram, fluoxetine): Caution. Restless legs syndrome documented with mianserin; side-effect aggregation is the mechanism. Introducing maca separately from any dose change keeps attribution clear.

  • Over-the-counter medicines (ibuprofen, acetaminophen, antacids, antihistamines): Monitor. No interaction is documented, and maca did not inhibit liver drug-processing enzymes, so the only plausible overlap is added gastrointestinal irritation alongside anti-inflammatory drugs, which food intake reduces.

  • Antihypertensives (amlodipine, lisinopril, losartan, hydrochlorothiazide): Monitor. Maca lowered diastolic pressure in one trial, so the effect is additive and could produce lightheadedness. Weekly seated pressure readings for the first month catch the drift.

  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, potassium, garlic extract, hibiscus, omega-3 fatty acids): Monitor. Additive diastolic lowering. Staggering introductions by two weeks traces any symptomatic drop to one agent.

  • Erectile-dysfunction drugs (sildenafil, tadalafil, vardenafil): Caution. Not a pharmacological interaction but a contamination one — maca products have been found spiked with unlicensed sildenafil analogues, risking unintended double dosing and hypotension.

  • Thyroid hormone replacement (levothyroxine, liothyronine): Caution. The glucosinolate goitrogen concern is theoretical, but cruciferous loads and levothyroxine absorption both respond to timing. Four hours’ separation between doses, with thyroid-stimulating hormone rechecked at 12 weeks, is the usual precaution.

  • Iron and zinc supplements: Monitor. Maca supplies both minerals in food quantities, so combined intake can overshoot upper limits. Maca’s contribution counts toward the total before a multivitamin is added.

  • Testosterone replacement therapy and androgen testing: Caution. Maca does not change actual testosterone, but it can distort immunoassay readings and so misdirect dose titration. Mass spectrometry confirms any surprising value.

  • Anti-doping-tested competition: Caution. Maca is not explicitly prohibited, yet assay interference can produce a falsely elevated testosterone result and an adverse analytical finding. Avoidance is the only reliable mitigation.

Populations who should avoid Maca:

  • Pregnant and breastfeeding women — safety data are absent, and the lead-contamination signal weighs heaviest here
  • Active liver disease or liver failure (Child-Pugh Class B or C) — one unreplicated case of acute liver injury is on record
  • Diagnosed prostate cancer, or prostate-specific antigen above 4 ng/mL under investigation — cell-culture data show androgen receptor and antigen gene upregulation
  • Children and adolescents under 18 — no trial has enrolled this group at any dose
  • Athletes subject to anti-doping testing — testosterone-assay interference creates sanction risk without a health benefit to offset it

Risk Mitigation Strategies

  • Heavy-metal-tested lots: A batch certificate of analysis showing lead below 0.5 µg per daily serving is the screen used, and it directly addresses the lead accumulation documented in a maca powder user.

  • Low starting dose with food: Protocols typically begin at 1,500 mg daily for two weeks before moving to 3,000 mg. Gastrointestinal upset is dose-related, and this is the cheapest way to avoid it.

  • Reanalysis of surprising testosterone results: A total testosterone above the sex-specific reference limit without matching clinical signs — 2.9 nmol/L in women, about 35 nmol/L in men — is rerun by mass spectrometry, which is immune to maca’s immunoassay interference.

  • Four-hour separation from levothyroxine: Takes the theoretical glucosinolate-absorption concern off the table and preserves stable thyroid replacement, with thyroid-stimulating hormone rechecked once at 12 weeks.

  • Introduction as a single change: No other supplement added and no medication dose changed for four weeks. Restless legs, lightheadedness or sleep disruption can then be attributed rather than guessed at.

  • Weekly seated blood pressure for one month: Catches additive diastolic lowering in anyone on antihypertensive medication or blood-pressure-lowering supplements before it becomes symptomatic.

  • Whole root powder over concentrated extracts: Alkaloid content varied from 56 to 598 parts per million across finished products, and trial evidence rests mostly on root powder rather than concentrates.

Therapeutic Protocol

  • Standard dose: 1,500–3,000 mg of dried maca root powder daily, oral, with food. This is the range in most positive trials; 3,000 mg separated from placebo where 1,500 mg did not. The Korean trial used 5,000 mg.

  • Concentrated-extract alternative: 2,400 mg daily of dry maca extract for erectile function, or 3,000 mg daily of spray-dried black or red extract for mood and energy — the regimens used by Zenico and by the Gonzales group respectively.

  • Gelatinized versus raw powder: Gelatinization removes starch by heat and is the form used in the Peruvian trials and the Korean aging-male trial. Practitioners favour it for digestibility; raw powder has equivalent trial support.

  • Phenotype selection: Andean practice and the Cayetano Heredia group favour red maca for mood, energy and prostate outcomes and black maca for memory and sperm endpoints; yellow is the commodity default.

  • Time of day: Morning, with breakfast. Maca is mildly stimulating in reported experience and evening dosing is the commonly cited cause of disturbed sleep; all trial protocols dosed before or with meals.

  • Single versus split dosing: Both work. The Korean trial split roughly 5,000 mg across three daily doses before food, two 1,000 mg tablets each time; Peruvian and Italian trials used a single daily dose. Splitting reduces gastrointestinal upset.

  • Half-life: Not established in humans. Macamides are fat-soluble with short animal half-lives, which is why daily dosing rather than intermittent use is universal in trials and why effects took 8–12 weeks to appear.

  • Sex-based differences: No dose separation exists. Women were studied at 3,300–3,500 mg for menopausal symptoms, men at 1,500–5,000 mg for desire and function; the ranges overlap and no trial compared sexes directly.

  • Age considerations: Trials span 21 to the mid-sixties at identical doses. Beyond 70 there is no evidence; the conservative approach is the lower 1,500 mg end, given slower gastrointestinal transit and more polypharmacy.

  • Genetic polymorphisms: No pharmacogenetic testing guides maca dosing. The FAAH C385A variant is the mechanistically plausible candidate, since macamides inhibit that enzyme, but no trial has genotyped participants.

  • Baseline biomarkers: Blood pressure, thyroid-stimulating hormone, haemoglobin and testosterone before starting. These are the four parameters that moved, or appeared to move, in trials, and baseline values make later readings interpretable.

  • Pre-existing conditions: Symptomatic menopause, low desire, antidepressant-induced sexual dysfunction and aging-male symptoms are the states with trial support. Normal baseline function predicted no measurable response.

  • Competing approaches: Conventional practice uses hormone therapy for menopausal symptoms and phosphodiesterase-5 inhibitors (drugs such as sildenafil) for erectile dysfunction, both with larger effects and longer safety records; integrative practice uses maca as a non-hormonal option. Neither is the default.

Discontinuation & Cycling

  • Lifelong or short-term: Trial exposure ran 2 to 16 weeks, so continuous use beyond four months is untested. Traditional Andean use is dietary and lifelong, which is the only long-duration evidence available.

  • Withdrawal effects: None documented. No trial reported rebound symptoms on stopping, and maca produces no dependence signal in the reporting record.

  • Tapering: Not required. Maca can be stopped outright; the case of lead exposure resolved simply by discontinuation, with no tapering step described.

  • Cycling for efficacy: No tolerance has been demonstrated, so cycling has no efficacy rationale. A pragmatic pattern is 12 weeks on, 4 weeks off, which doubles as a placebo-control test on personal response.

  • Stopping to test attribution: A four-week break is the cheapest way to establish whether a perceived benefit tracks the supplement, given how large placebo responses are on self-rated desire endpoints.

  • Reasons to stop permanently: A lead result above the detection floor, an unexplained testosterone spike, new restless legs on an antidepressant, or no symptom change after 12 weeks at 3,000 mg daily.

Sourcing and Quality

  • Origin matters more than brand: Junín-plateau Peruvian root is the material used in essentially all trial work; Yunnan-grown maca expanded supply after 2010 with a different phytochemical profile and less trial support.

  • Heavy-metal testing is the decisive check: A batch certificate of analysis reporting lead, cadmium and arsenic is what the trade supplies. One of eleven retail products failed independent lead testing, and lead was traced into a user’s blood.

  • Third-party verification: NSF, USP and Informed Choice marks, and a ConsumerLab-approved listing, are the available signals. Identity testing matters because nearly half of products in an analysis on Examine lacked a detectable maca marker compound.

  • Form: Whole dried root powder, raw or gelatinized, carries the trial evidence. Concentrated extracts vary from 56 to 598 parts per million in alkaloid content and are not interchangeable by weight with root powder.

  • Phenotype labelling: Products stating the colour — black, red, yellow — and its percentage allow the phenotype-specific evidence to be applied. Unlabelled “maca” is a blend, usually yellow-dominant.

  • Adulteration screening: Products marketed explicitly for erectile performance carry the documented adulteration risk; one product in that analysis contained thiosildenafil. Plain single-ingredient root powder avoids this class of product entirely.

  • Reputable suppliers: ConsumerLab has approved products from Gaia Herbs, Navitas, Nature’s Way, Solaray and Swanson in its testing round; Symphony Natural Health markets the standardized phenotype blends used in several menopause trials.

Practical Considerations

  • Time to effect: Eight to twelve weeks. Desire separated from placebo at week 8 in the Peruvian trial, and symptom scales moved at 6 to 12 weeks elsewhere. Nothing in this literature works in days.

  • Underdosing: The most common error. 1.5 g daily failed where 3 g succeeded in the antidepressant trial, and capsules typically hold 500 mg, so six capsules daily is the trial-equivalent dose.

  • Evening dosing: The second common error, and the reported cause of disturbed sleep. Morning administration with food resolves it.

  • Expecting a hormonal effect: Maca does not raise testosterone. Buying it as a testosterone booster guarantees disappointment; a systematic review of such products found maca among those that fail to move total testosterone.

  • Regulatory status: Sold as a food and dietary supplement in the United States and European Union, with no pre-market approval, no approved therapeutic indication, and no medical-society guidance. European regulators have raised alkaloid-content concerns.

  • No professional-body guidance is relied on here: No medical society or advocacy organization has issued a maca position, so no organizational guidance is cited; the evidence used is peer-reviewed trials and reviews, with industry authorship flagged where present.

  • Payer incentives: Insurers and national health systems fund hormone therapy and generic phosphodiesterase-5 inhibitors but not supplements, giving institutions no financial reason to sponsor maca trials — a structural reason the evidence base stays small and industry-funded.

  • Cost and access: Inexpensive and unrestricted — roughly 10 to 12 cents per gram of powder, so a trial-equivalent 3 g daily costs well under 50 cents per day, with no prescription and wide retail availability.

Interaction with Foundational Habits

  • Sleep: Potentially blunting, and direction depends on timing. Disturbed sleep is among the reported side effects, consistent with mild central stimulation from raised endocannabinoid and dopamine signalling. Morning dosing with food is the practical fix; no controlled trial has measured sleep architecture on maca.

  • Nutrition: Direct and additive. Maca is a starchy cruciferous food supplying zinc, iron, fibre and gamma-aminobutyric acid, so it counts toward mineral intake rather than sitting outside it. Adequate dietary iodine offsets the theoretical glucosinolate concern; taking it with a meal reduces gastrointestinal upset.

  • Exercise: No interaction demonstrated. Controlled trials in cyclists and basketball players found no performance benefit against placebo, and no evidence suggests maca blunts training adaptation either. Timing relative to workouts is therefore unconstrained; the one caution is anti-doping assay interference for tested competitors.

  • Stress management: Indirect and mild. Maca is marketed as an adaptogen but has not been shown to alter cortisol or the hypothalamic-pituitary-adrenal axis, the body’s central stress-hormone circuit. What trials do show is reduced anxiety and depression subscale scores in menopausal women, which is a symptom effect rather than a hormonal one.

Monitoring Protocol & Defining Success

Baseline testing before the first dose covers the four parameters that shifted, or appeared to shift, in trials: seated blood pressure, thyroid-stimulating hormone, a complete blood count with ferritin, and total testosterone. Blood lead belongs in the baseline panel for anyone already using an untested powder. Success is defined by symptom scales, not laboratory values, so a starting score on a validated questionnaire matters more than any blood result.

Ongoing monitoring is light. Seated blood pressure weekly for the first month, then monthly. Bloods are repeated at 12 weeks — the point by which every documented benefit has appeared — covering thyroid-stimulating hormone, liver enzymes, haemoglobin and, where relevant, prostate-specific antigen. After that, every 6 to 12 months, or sooner if the product lot changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood lead Below 1 µg/dL Root powder has carried lead into a user’s blood Conventional adult action level is 3.5 µg/dL, far above the functional target; venous draw; repeated 3 months after any lot change
Diastolic blood pressure 70–80 mmHg Maca lowered diastolic pressure in one trial; additive with antihypertensives Not a laboratory test; seated, after 5 minutes rest, averaged over two readings; weekly for the first month
Total testosterone 500–800 ng/dL in men; 15–70 ng/dL in women Anchors response and exposes assay interference Conventional male reference range runs 264–916 ng/dL, far wider than the functional target; immunoassay reads falsely high on maca — implausible values are confirmed by liquid chromatography–mass spectrometry; drawn fasting before 10 a.m.
TSH 0.5–2.0 mIU/L Screens the theoretical glucosinolate goitrogen concern TSH is thyroid-stimulating hormone, the pituitary signal controlling thyroid output; conventional range runs to 4.5 mIU/L; paired with free thyroxine; morning draw, before levothyroxine if taken
Haemoglobin and ferritin Haemoglobin 13.5–15.0 g/dL in men, 12.5–14.0 in women; ferritin 50–125 ng/mL Maca lowered haemoglobin in highlanders with abnormally high levels Part of a complete blood count; conventional ferritin reference runs about 30–400 ng/mL, far wider than the functional band; ferritin rises with inflammation, so it is read alongside high-sensitivity C-reactive protein (a general marker of inflammation)
PSA Below 1.0 ng/mL under age 60; below 2.0 ng/mL thereafter Cell-culture work showed red maca raising antigen gene expression PSA is prostate-specific antigen, a prostate protein measured in blood; the conventional referral cutoff is 4.0 ng/mL, well above the functional target; no change was seen in the 12-week human trial; ejaculation and cycling are avoided for 48 hours before the draw
Fasting glucose and HbA1c Glucose 75–86 mg/dL; HbA1c 4.9–5.4% Black maca lowered blood glucose in a controlled trial HbA1c is glycated haemoglobin, a three-month average of blood sugar; conventional thresholds are 100 mg/dL and 5.7%, looser than the functional targets; 8–12 hour fast
ALT and AST ALT below 25 U/L in men, below 20 U/L in women; AST below 25 U/L One unreplicated case of acute liver injury is attributed to maca ALT and AST are alanine and aspartate aminotransferase, liver enzymes; conventional upper limits are roughly double these; rechecked at 12 weeks, with maca stopped on any unexplained rise

Qualitative markers carry more weight than any of the above, since maca’s documented benefits are symptomatic:

  • Sexual desire, rated on the same simple scale weekly rather than recalled
  • Menopausal symptom burden — hot flushes, night sweats, mood volatility — scored monthly
  • Energy and perceived exertion during ordinary daily activity
  • Mood stability, and specifically anxiety and low mood, tracked separately from energy
  • Sleep onset and continuity, which is where an unwanted effect would show first
  • Urinary flow, urgency and night-time voiding frequency in men over 50

Emerging Research

  • Lower urinary tract symptoms trial: NCT07816172 is a Phase 2, placebo-controlled trial of a maca root preparation in 200 men with lower urinary tract symptoms, due to start September 2026 — the first adequately powered test of the urinary finding.

  • Male sexual dysfunction trial: NCT05891327 tests maca extract against placebo in 60 men with sexual dysfunction at Taipei Medical University, with erectile function and erection hardness as the registered endpoints; status is unconfirmed since 2024.

  • Endurance recovery trial: NCT05779488 gives maca or placebo to 50 healthy adults after strenuous endurance exercise, targeting the recovery and immune endpoints that the null performance trials did not measure.

  • Postmenopausal sexual function trial: NCT02624648 enrolled 144 postmenopausal women for maca versus placebo on the Female Sexual Function Index and Beck Depression Inventory — the largest trial of this outcome, with results not yet reported.

  • Evidence that could weaken the case: The pooled semen-quality analysis by Lee et al., 2022 and the null basketball trial by Wu et al., 2025 show what happens when maca endpoints are properly placebo-controlled; further trials of this design would likely shrink the remaining claims.

  • Evidence that could strengthen it: Phenotype-specific work, argued for by Minich et al., 2024, is the main untested lever — if red and black maca genuinely differ in effect, the mixed-phenotype trials have been diluting real signals.

  • Mechanistic direction to watch: Macamide inhibition of fatty acid amide hydrolase, reviewed by Vera-López et al., 2024, is the only mechanism that explains central effects without hormonal change and would make maca dose-standardizable by macamide content.

  • Product-quality research: The alkaloid quantification method of Le et al., 2024 is the first validated assay for maca’s potentially toxic alkaloids and could convert a regulatory concern into an enforceable specification.

Conclusion

Maca is an Andean root food, taken in gram quantities as a powder, with a narrow but reasonably consistent set of effects. The clearest is on sexual desire, which rises in men, in menopausal women and in people whose libido has been flattened by antidepressants — and it rises without any change in sex hormones, which is the most interesting thing about it. Menopausal symptom scores fall, and in older men both erectile and urinary symptom scores improve, though those gains are small in absolute terms. Claims about athletic performance and fertility do not survive placebo control.

The risks are modest and mostly about the product rather than the plant. Lead has been traced from retail powder into a user’s blood, some products have contained no detectable maca or a related unlicensed drug, and maca can distort testosterone blood tests badly enough to trigger a false alarm. Mild stomach upset is the usual complaint.

The evidence base is thin and financially entangled. Trials are small, several were authored by people employed by companies selling maca, and no insurer or health system has any reason to fund a larger one. That does not make the positive findings wrong, but the confidence the evidence can carry stays proportionate to the size and independence of what has actually been tested.

Top - Benefits - Risks - Protocol